"Provide a new potent brachytherapy tool for the treatment of cancers in
humans and animals that will be very effective in improving the lives of
The Company obtained clarification from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and
approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market
sector. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private
veterinary clinic consortiums.
you can edit this section directly in HTML ( templates > custom template > html )
Vivos Inc. EXPANDS ISOPET® TRADEMARK PROTECTION
Richland, WA, May 27, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL). Vivos Inc. previously filed to extend its IsoPet® trademark protection
We are pleased to report that the Commissioner for Trademarks at the U.S. Patent and Trademark Office has confirmed the filing and Certification of the ISOPET Madrid Protocol international
application for use in connection with “Isotopes for veterinary use; radio-isotope markers for therapeutic veterinary purposes” in Class 5.
The International Bureau of the World Intellectual Property Organization (“WIPO”) reviewed the international application and determined it met the Madrid Protocol filing requirements. WIPO has
registered the mark, published it in the WIPO Gazette of International Marks, and sent us the certificate of registration.